| Schedule of worldwide net revenues |
The following table details AbbVie’s worldwide net revenues: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | | | | | | | | | | | | | | | | | (in millions) | | 2025 | | 2024 | | 2025 | | 2024 | | | | | | | | Immunology | | | | | | | | | | | | | | | Skyrizi | United States | $ | 4,085 | | | $ | 2,778 | | | $ | 10,847 | | | $ | 6,774 | | | | | | | | | International | 623 | | | 427 | | | 1,709 | | | 1,166 | | | | | | | | | Total | $ | 4,708 | | | $ | 3,205 | | | $ | 12,556 | | | $ | 7,940 | | | | | | | | | Rinvoq | United States | $ | 1,559 | | | $ | 1,170 | | | $ | 4,231 | | | $ | 2,912 | | | | | | | | | International | 625 | | | 444 | | | 1,699 | | | 1,225 | | | | | | | | | Total | $ | 2,184 | | | $ | 1,614 | | | $ | 5,930 | | | $ | 4,137 | | | | | | | | | Humira | United States | $ | 619 | | | $ | 1,765 | | | $ | 2,165 | | | $ | 5,896 | | | | | | | | | International | 374 | | | 462 | | | 1,129 | | | 1,415 | | | | | | | | | Total | $ | 993 | | | $ | 2,227 | | | $ | 3,294 | | | $ | 7,311 | | | | | | | | | Neuroscience | | | | | | | | | | | | | | | Vraylar | United States | $ | 931 | | | $ | 873 | | | $ | 2,592 | | | $ | 2,338 | | | | | | | | | International | 3 | | | 2 | | | 7 | | | 5 | | | | | | | | | Total | $ | 934 | | | $ | 875 | | | $ | 2,599 | | | $ | 2,343 | | | | | | | | | Botox Therapeutic | United States | $ | 825 | | | $ | 708 | | | $ | 2,323 | | | $ | 1,988 | | | | | | | | | International | 160 | | | 140 | | | 456 | | | 422 | | | | | | | | | Total | $ | 985 | | | $ | 848 | | | $ | 2,779 | | | $ | 2,410 | | | | | | | | | Ubrelvy | United States | $ | 344 | | | $ | 261 | | | $ | 907 | | | $ | 685 | | | | | | | | | International | 10 | | | 8 | | | 25 | | | 18 | | | | | | | | | Total | $ | 354 | | | $ | 269 | | | $ | 932 | | | $ | 703 | | | | | | | | | Qulipta | United States | $ | 252 | | | $ | 168 | | | $ | 661 | | | $ | 442 | | | | | | | | | International | 36 | | | 8 | | | 87 | | | 15 | | | | | | | | | Total | $ | 288 | | | $ | 176 | | | $ | 748 | | | $ | 457 | | | | | | | | | Vyalev | United States | $ | 53 | | | $ | — | | | $ | 81 | | | $ | — | | | | | | | | | International | 85 | | | 28 | | | 218 | | | 55 | | | | | | | | | Total | $ | 138 | | | $ | 28 | | | $ | 299 | | | $ | 55 | | | | | | | | | Duodopa | United States | $ | 16 | | | $ | 24 | | | $ | 56 | | | $ | 72 | | | | | | | | | International | 80 | | | 87 | | | 233 | | | 267 | | | | | | | | | Total | $ | 96 | | | $ | 111 | | | $ | 289 | | | $ | 339 | | | | | | | | | Other Neuroscience | United States | $ | 42 | | | $ | 54 | | | $ | 148 | | | $ | 172 | | | | | | | | | International | 4 | | | 2 | | | 12 | | | 11 | | | | | | | | | Total | $ | 46 | | | $ | 56 | | | $ | 160 | | | $ | 183 | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three months ended September 30, | | Nine months ended September 30, | | | | | | | | | | | | | | | | | (in millions) | | 2025 | | 2024 | | 2025 | | 2024 | | | | | | | | Oncology | | | | | | | | | | | | | | | Imbruvica | United States | $ | 507 | | | $ | 618 | | | $ | 1,579 | | | $ | 1,823 | | | | | | | | | Collaboration revenues | 199 | | | 210 | | | 619 | | | 676 | | | | | | | | | Total | $ | 706 | | | $ | 828 | | | $ | 2,198 | | | $ | 2,499 | | | | | | | | | Venclexta | United States | $ | 341 | | | $ | 340 | | | $ | 974 | | | $ | 921 | | | | | | | | | International | 385 | | | 337 | | | 1,108 | | | 1,007 | | | | | | | | | Total | $ | 726 | | | $ | 677 | | | $ | 2,082 | | | $ | 1,928 | | | | | | | | | Elahere | United States | $ | 150 | | | $ | 139 | | | $ | 453 | | | $ | 331 | | | | | | | | | International | 20 | | | — | | | 55 | | | — | | | | | | | | | Total | $ | 170 | | | $ | 139 | | | $ | 508 | | | $ | 331 | | | | | | | | | Epkinly | Collaboration revenues | $ | 44 | | | $ | 31 | | | $ | 129 | | | $ | 82 | | | | | | | | | International | 25 | | | 12 | | | 61 | | | 24 | | | | | | | | | Total | $ | 69 | | | $ | 43 | | | $ | 190 | | | $ | 106 | | | | | | | | | Other Oncology | United States | $ | 11 | | | $ | — | | | $ | 13 | | | $ | — | | | | | | | | | Aesthetics | | | | | | | | | | | | | | | Botox Cosmetic | United States | $ | 379 | | | $ | 414 | | | $ | 1,084 | | | $ | 1,253 | | | | | | | | | International | 258 | | | 257 | | | 801 | | | 780 | | | | | | | | | Total | $ | 637 | | | $ | 671 | | | $ | 1,885 | | | $ | 2,033 | | | | | | | | | Juvederm Collection | United States | $ | 98 | | | $ | 105 | | | $ | 278 | | | $ | 349 | | | | | | | | | International | 155 | | | 153 | | | 466 | | | 549 | | | | | | | | | Total | $ | 253 | | | $ | 258 | | | $ | 744 | | | $ | 898 | | | | | | | | | Other Aesthetics | United States | $ | 265 | | | $ | 272 | | | $ | 817 | | | $ | 828 | | | | | | | | | International | 38 | | | 38 | | | 128 | | | 119 | | | | | | | | | Total | $ | 303 | | | $ | 310 | | | $ | 945 | | | $ | 947 | | | | | | | | | Eye Care | | | | | | | | | | | | | | | Ozurdex | United States | $ | 32 | | | $ | 33 | | | $ | 92 | | | $ | 102 | | | | | | | | | International | 85 | | | 86 | | | 273 | | | 272 | | | | | | | | | Total | $ | 117 | | | $ | 119 | | | $ | 365 | | | $ | 374 | | | | | | | | | Lumigan/Ganfort | United States | $ | 42 | | | $ | 58 | | | $ | 142 | | | $ | 129 | | | | | | | | | International | 55 | | | 58 | | | 164 | | | 181 | | | | | | | | | Total | $ | 97 | | | $ | 116 | | | $ | 306 | | | $ | 310 | | | | | | | | | Alphagan/Combigan | United States | $ | 9 | | | $ | 26 | | | $ | 35 | | | $ | 54 | | | | | | | | | International | 38 | | | 36 | | | 108 | | | 116 | | | | | | | | | Total | $ | 47 | | | $ | 62 | | | $ | 143 | | | $ | 170 | | | | | | | | | Other Eye Care | United States | $ | 138 | | | $ | 123 | | | $ | 399 | | | $ | 421 | | | | | | | | | International | 110 | | | 105 | | | 316 | | | 321 | | | | | | | | | Total | $ | 248 | | | $ | 228 | | | $ | 715 | | | $ | 742 | | | | | | | | | Other Key Products | | | | | | | | | | | | | | | Mavyret | United States | $ | 146 | | | $ | 147 | | | $ | 472 | | | $ | 458 | | | | | | | | | International | 166 | | | 155 | | | 521 | | | 562 | | | | | | | | | Total | $ | 312 | | | $ | 302 | | | $ | 993 | | | $ | 1,020 | | | | | | | | | Creon | United States | $ | 368 | | | $ | 338 | | | $ | 1,127 | | | $ | 995 | | | | | | | | | Linzess/Constella | United States | $ | 315 | | | $ | 225 | | | $ | 701 | | | $ | 693 | | | | | | | | | International | 11 | | | 9 | | | 31 | | | 28 | | | | | | | | | Total | $ | 326 | | | $ | 234 | | | $ | 732 | | | $ | 721 | | | | | | | | | All other | | $ | 660 | | | $ | 726 | | | $ | 2,010 | | | $ | 2,280 | | | | | | | | | Total net revenues | $ | 15,776 | | | $ | 14,460 | | | $ | 44,542 | | | $ | 41,232 | | | | | | | |
|